Jennison Associates
VNDA icon

Jennison Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

Jennison Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-450,000
Closed -$4.94M – 736
2013
Q3 		$4.94M Buy
+450,000
New +$4.81M 0.01% 507

Other funds holding VNDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates's VNDA Position: Q4 2013 in Review

Jennison Associates sold out of Vanda Pharmaceuticals (VNDA) in Q4 2013, closing a stake of 450,000 shares — an estimated $4.94M sold.

Jennison Associates first reported a position in VNDA in Q3 2013 and held it in 1 quarter. The position peaked at $4.94M in Q3 2013. 86 funds tracked by Wall St. Rank hold VNDA as of Q4 2013.

  • Jennison Associates reported no remaining Vanda Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Jennison Associates sold 450,000 Vanda Pharmaceuticals shares in Q4 2013, an estimated $4.94M.
  • Jennison Associates first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Jennison Associates's Vanda Pharmaceuticals position peaked at $4.94M in Q3 2013.
  • 86 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2013.

Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.